Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from InflaRx ( (IFRX) ) is now available.
On April 2, 2026, InflaRx N.V. announced it had convened its 2026 annual general meeting of shareholders for April 23, 2026 in Amsterdam, setting March 26, 2026 as the record date and outlining attendance and proxy procedures for registered and beneficial owners. The AGM agenda includes approval of the 2025 statutory accounts, discussion of the company’s no-dividend policy, appointment of KPMG as external auditor for 2026, discharge of directors for 2025, reappointment of CEO and co-founder Niels Riedemann and other board members, renewal of share issuance and buyback authorities, an amendment to the articles of association and approval of a new long-term incentive plan, signaling a focus on governance continuity and capital-structure flexibility.
The proposed reappointment of Riedemann as executive director through the 2030 AGM underscores management stability at a time when the company continues to prioritize reinvestment over shareholder payouts. Shareholders will also vote on extending the board’s powers to issue shares, exclude pre-emption rights and repurchase stock, as well as on a new long-term incentive plan, steps that may affect future dilution, executive alignment and InflaRx’s ability to respond strategically to financing and transactional opportunities.
The most recent analyst rating on (IFRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on InflaRx stock, see the IFRX Stock Forecast page.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, sizable ongoing losses, and persistent cash burn). Technicals are roughly neutral with limited momentum, while valuation metrics offer little support due to losses and no indicated dividend yield.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V. is a Germany-based biopharmaceutical company focused on developing anti-inflammatory therapies, particularly in complement immunology. Listed in the United States as a foreign private issuer, the company relies on equity financing to fund research, development and potential commercialization of its pipeline rather than on dividend distributions.
Average Trading Volume: 407,755
Technical Sentiment Signal: Sell
Current Market Cap: $65.28M
See more data about IFRX stock on TipRanks’ Stock Analysis page.